EMA shuts revolving door between industry and experts
This article was originally published in Scrip
The European Medicines Agency is jamming the "revolving door" between its experts and the pharmaceutical industry. According to newly updated rules, experts and committee members who declare intentions to work for a pharma company will have to cease their involvement in any medicines assessment. NGOs have welcomed the move, but say the EMA still needs to go further to guarantee real transparency and independence from the industry.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.